Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

Clinical trial NCT06912087 · RECRUITING

Trial details

NCT number: NCT06912087
Sponsor: University of Chicago
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Head and Neck Neoplasms Carcinoma, Squamous Cell Neoplasm Recurrence, Local Neoplasm Metastasis Recurrent Squamous Cell Carcinoma Metastatic Squamous Cell Carcinoma

Start date: 2025-09-29
Primary completion: 2027-06-05
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.